TriangleNCT04985604 · OUTCOME
Time to Response
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- Inter-Quartile Range
- Time frame
- Up to 23 months
What was measured
Time to Response was defined in participants with best overall response of complete response or partial response as determined by Investigator. It is the interval from the date of the first dose to date of first documentation of tumor response that was subsequently confirmed by investigator assessment.
Analysis population: Participants in the Efficacy Analysis Set who have a confirmed response of CR or PR were analyzed.
Groups in this outcome
Melanoma Cohort
Adult participants (≥ 18 years) were administered Tovorafenib 600 mg orally (PO) once weekly (QW).
Tissue Agnostic Cohort
Adult participants (≥ 18 years) were administered Tovorafenib 600 mg PO QW.
| Group | Source count |
|---|---|
| Melanoma Cohort | 4 |
| Tissue Agnostic Cohort | 6 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Melanoma Cohort | 1.76 | Not reported | 1.66 | 6.44 | Not reported |
| Tissue Agnostic Cohort | 1.82 | Not reported | 1.77 | 1.87 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.66
- upper Limit
- 6.44
- value
- 1.76
- group Id
- OG001
- lower Limit
- 1.77
- upper Limit
- 1.87
- value
- 1.82
- denoms
- counts
- group Id
- OG000
- value
- 4
- group Id
- OG001
- value
- 6
- units
- Participants
- description
- Time to Response was defined in participants with best overall response of complete response or partial response as determined by Investigator. It is the interval from the date of the first dose to date of first documentation of tumor response that was subsequently confirmed by investigator assessment.
- dispersion Type
- Inter-Quartile Range
- groups
- description
- Adult participants (≥ 18 years) were administered Tovorafenib 600 mg orally (PO) once weekly (QW).
- id
- OG000
- title
- Melanoma Cohort
- description
- Adult participants (≥ 18 years) were administered Tovorafenib 600 mg PO QW.
- id
- OG001
- title
- Tissue Agnostic Cohort
- param Type
- MEDIAN
- population Description
- Participants in the Efficacy Analysis Set who have a confirmed response of CR or PR were analyzed.
- reporting Status
- POSTED
- time Frame
- Up to 23 months
- title
- Time to Response
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice